The Shenzhen Stock Exchange in the year of the monkey’s first letters of concern South China biologi-cosmax

The Shenzhen Stock Exchange in the year of the monkey’s first letters of concern: South China biological plan set by why fickle hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulation trading client Sina Level2:A shares Sina speed Kanpan finance client: the most profitable investors in each by the reporter Huang Xia of the spring Festival, the Shenzhen Stock Exchange issued the first year of the regulatory letter. Due to Nanhua (000504, closing price of 18.81 yuan) in 2015, 600 million yuan fixed increase plan sudden abortion, replaced by similar content in 2016 fixed increase plan. This situation has attracted the attention of the Shenzhen stock exchange. South China biological 600 million yuan in 2015 set by the case suddenly abortion, but a similar project "shrink" version of the new plan, in this regard, the Shenzhen Stock Exchange after the opening of Spring Festival, a year of the first letter of supervision. The letter said that the South China biological original program has been in 2015 fourth extraordinary general meeting by the end of 2015, the issuance of non-public shares only after the ninth session of the eleventh board and approved by the Shenzhen Stock Exchange require the company to explain the review process is not sufficient, and please sponsor and broker verification and comment. The Shenzhen Stock Exchange also asked the company to elaborate and disclose the reasons for the termination of the original program and the reasons for the new program and the difference between the new and the new schemes. In addition, also require that planning process of the new program, including but not limited to the time, place, manner, participation and informed staff, insider information registration and security planning. Insider information, whether or not the insider has leaked the information or used the information to conduct insider trading. "Daily economic news" reporter found that, in 2015 the fixed increase plan and 2016 new plan is extremely similar, just "shrink". In January 2015, the South China biological announcement, the company intends to issue 95 million shares at a price of 6.35 yuan directional shares, raising not more than 603 million yuan to invest in stem cells and immune cell storage project, cell and tissue engineering center projects and supplement working capital and repayment of debt. After the completion of the project, more than 320 days of stem cells and immune cell processing capacity will be formed. It is worth mentioning that in 2015 the issuance of non-public shares by the company in January 27, 2015 held the ninth session of the board of directors of the first extraordinary meeting, held in September 28, 2015 eighth extraordinary meeting of the board of directors on October 14, 2015, held in 2015 fourth extraordinary general meeting. In November 6, 2015, the company received the Commission issued the "China Commission administrative license application acceptance notice" (No. 153133), the Commission shall be submitted to the company’s non-public offering of shares of administrative license application materials were reviewed, that the application materials are complete and meet the statutory form, decide to accept the application for administrative license. Interestingly, in February 6, 2016, lasted a year and the line set by the case was terminated in 2015, also announced an Nanhua biological plan set by the new. In 2016, the new scheduled increase plan said that the non-public offering of shares should be discussed

深交所猴年首张关注函:南华生物定增预案为何善变 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经Level2:A股极速看盘 新浪财经客户端:最赚钱的投资者都在用   ◎每经记者 黄霞   春节刚过,深交所就发出了猴年首张监管函。由于南华生物(000504,收盘价18.81元)2015年6亿元定增预案突然流产,取而代之的是内容相似的2016年定增预案。这一情况受到了深交所关注。   南华生物2015年6亿元定增案突然流产,却又发出了项目相似的“缩水版”新预案,对此,深交所在春节开市后,发出了猴年首张监管函。   该关注函表示,南华生物原方案已经2015年第四次临时股东大会审议通过,此次终止2015年非公开发行股票事项仅经过第九届董事会第十一次临时会议审议通过,深交所要求公司说明审议程序是否充分,并请保荐机构及券商核查并发表意见。深交所还要求公司详细说明并披露终止原方案并推进新方案的原因和新旧方案的差异情况对比表。此外,还要求说明此次新方案的筹划过程,包括但不限于筹划的时间、地点、方式、参与及知情人员、内幕信息登记及保密情况。相关内幕信息知情人是否存在泄露该信息,或利用该信息进行内幕交易的情形。   《每日经济新闻》记者对比发现,2015年的定增预案和2016年的新预案极其相似,只是“缩水”了。   2015年1月,南华生物公告,公司拟以6.35元 股的价格定向增发9500万股,募资不超过6.03亿元投向干细胞和免疫细胞储存库项目、细胞与组织工程实验中心项目和补充流动资金及偿还债务。项目建成以后,将形成超过320份 天的干细胞及免疫细胞处理能力。   值得一提的是,2015年非公开发行股票事项经公司于2015年1月27日召开的第九届董事会第一次临时会议、2015年9月28日召开的董事会第八次临时会议、2015年10月14日召开的2015年第四次临时股东大会审议通过。2015年11月6日,公司收到证监会出具的《中国证监会行政许可申请受理通知书》(153133号),证监会依法对公司提交的非公开发行股票行政许可申请材料进行了审查,认为该申请材料齐全,符合法定形式,决定对该行政许可申请予以受理。   有意思的是,2016年2月6日,历时一年本该成行的2015年定增案被终止,南华生物同时公告抛出了新的定增预案。2016年新定增预案称,拟非公开发行股票数量不超过5000万股,拟募集资金总额不超过2.9亿元,用于干细胞储存库项目、细胞与组织工程实验中心项目、补充流动资金及偿还银行债务。值得一提的是,核心募投项目的干细胞和免疫细胞储存库中,干细胞及免疫细胞处理能力从320份 天下降为150份 天。   南华生物表示,考虑到目前宏观环境、资本市场整体情况等诸多因素,公司决定终止该次非公开发行股票事项,并向证监会申请撤回该次非公开发行申请文件。   《每日经济新闻》记者注意到,虽然募资规模发生变化,却不改南华生物转型干细胞产业的初衷,正是“干细胞”成就了*ST传媒成为南华生物。 进入【新浪财经股吧】讨论相关的主题文章:

Both comments and pings are currently closed.

Comments are closed.